- |||||||||| Trial completion, Trial completion date, Trial primary completion date: Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer (clinicaltrials.gov) - Jul 19, 2018
P=N/A, N=2545, Completed, Trial completion date: Dec 2020 --> Feb 2018 | Active, not recruiting --> Terminated; Low accrual Active, not recruiting --> Completed | Trial completion date: Jan 2100 --> Jun 2018 | Trial primary completion date: Jan 2100 --> Jun 2018
- |||||||||| Enrollment closed, Enrollment change: Busulfan, Cyclophosphamide, and Melphalan or Busulfan and Fludarabine Phosphate Before Donor Hematopoietic Cell Transplant in Treating Younger Patients With Juvenile Myelomonocytic Leukemia (clinicaltrials.gov) - Nov 30, 2016
P2, N=30, Active, not recruiting, Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2014 --> Dec 2014 Suspended --> Active, not recruiting | N=145 --> 30
- |||||||||| NN1213 / Novo Nordisk
Trial completion: Traumeel (clinicaltrials.gov) - Jan 5, 2016 P=N/A, N=195, Completed, Recruiting --> Suspended Active, not recruiting --> Completed
- |||||||||| fludarabine IV / Generic mfg., mycophenolate mofetil / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date, Combination therapy, IO biomarker, Post-transplantation: Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer (clinicaltrials.gov) - Sep 1, 2015 P=N/A, N=5, Completed, Recruiting --> Active, not recruiting | N=18 --> 12 | Trial primary completion date: Jan 2018 --> Apr 2015 Recruiting --> Completed | N=20 --> 5 | Trial primary completion date: Dec 2015 --> Nov 2014
- |||||||||| Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi, Mylotarg (gemtuzumab ozogamicin) / UCB, PDL, Pfizer
Enrollment change, Combination therapy: Allogenic Stem Cell Transplantation in Patients With High Risk CD33+ AML/MDS/JMML (clinicaltrials.gov) - Apr 22, 2015 P1, N=12, Terminated, Active, not recruiting --> Completed | N=88 --> 6 | Trial primary completion date: Sep 2014 --> Dec 2011 N=16 --> 12
- |||||||||| Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Enrollment change, Trial termination, Trial primary completion date: Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant (clinicaltrials.gov) - Apr 13, 2015 P2, N=11, Terminated, Trial primary completion date: Mar 2015 --> Sep 2015 N=28 --> 11 | Recruiting --> Terminated | Trial primary completion date: Dec 2015 --> Oct 2014; Replaced by another protocol
- |||||||||| Jakafi (ruxolitinib) / Incyte
Trial completion, Enrollment change, Trial primary completion date, Tumor mutational burden: INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease (clinicaltrials.gov) - Oct 23, 2014 P1, N=49, Completed, Trial primary completion date: Mar 2014 --> Mar 2015 Active, not recruiting --> Completed | N=106 --> 49 | Trial primary completion date: May 2015 --> Oct 2014
|